Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STC-CI-01 appears to be a code name for an investigational drug or biologic related to stanniocalcin 1 (STC1), a glycoprotein hormone implicated in various physiological and pathological processes. Stanniocalcin 1 is known for its role in modulating mitochondrial function, calcium transport, and cellular metabolism. In cancer biology, STC1 has been identified as a phagocytosis checkpoint that enables tumor immune evasion by interacting with calreticulin (CRT) and inhibiting antigen-presenting cell activity. Targeting the STC1/CRT axis is being explored as a novel immunotherapeutic approach to overcome resistance to checkpoint blockade therapies in oncology. Additionally, stanniocalcin-1-based therapies have been investigated for ocular diseases such as retinal disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on STC-CI-01.